[Adjuvant interferon alpha in renal carcinoma with a high risk of recurrence. Multicenter pilot study].
Twenty-eight consecutive patients submitted to radical nephrectomy for Robson's stage II-III renal cell carcinoma underwent adjuvant recombinant a-2b interferon, 5 MUI s.c. 3 times a week, for 6 consecutive months. Home-feasibility of this therapy resulted easy. The most frequent acute (flu-like syndrome) and late (myalgia, fatigue, anorexia) side effects did not affect normal daily life of patients. Eight (28.5%) patients had WHO grade < or = 2 biochemical and hematological toxicity, that normalized after a reduction or a temporarily suspension of therapy. Twenty-seven patients were evaluable for response. Out of these, 7 (26%) relapsed after a 16 months median follow-up.
Pizzocaro
G
G
Istituto Nazionale Tumori, Milano.
Piva
L
L
Faustini
M
M
Nicolai
N
N
Salvioni
R
R
Pisani
E
E
Maggioni
A
A
Mandressi
A
A
Dormia
E
E
Minervini
S
S
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D010865:Pilot Projects; D011994:Recombinant Proteins; D012306:Risk; D016896:Treatment Outcome
D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Alfa-interferone adiuvante nel carcinoma renale ad alto rischio di ricaduta. Studio pilota multicentrico.